➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Mallinckrodt
Merck
Boehringer Ingelheim
Medtronic

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOLINZA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Zolinza

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00121225 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed National Cancer Institute (NCI) Phase 2 2005-09-01 This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
NCT00127101 An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) Terminated Merck Sharp & Dohme Corp. Phase 1 2005-09-01 This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients who have failed at least one prior systemic therapy.
NCT00132002 Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer Terminated National Cancer Institute (NCI) Phase 2 2005-06-01 This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive stage IV breast cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
NCT00132028 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed National Cancer Institute (NCI) Phase 2 2005-09-01 This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory advanced Hodgkin's lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zolinza

Condition Name

Condition Name for Zolinza
Intervention Trials
Unspecified Adult Solid Tumor, Protocol Specific 10
Lymphoma 10
Recurrent Adult Acute Myeloid Leukemia 9
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zolinza
Intervention Trials
Lymphoma 33
Leukemia 22
Lymphoma, Non-Hodgkin 17
Leukemia, Myeloid, Acute 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zolinza

Trials by Country

Trials by Country for Zolinza
Location Trials
United States 505
Canada 33
Japan 5
Australia 5
France 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zolinza
Location Trials
Texas 40
California 31
Pennsylvania 29
New York 25
Maryland 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zolinza

Clinical Trial Phase

Clinical Trial Phase for Zolinza
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 2
Phase 2 48
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zolinza
Clinical Trial Phase Trials
Completed 59
Active, not recruiting 33
Recruiting 26
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zolinza

Sponsor Name

Sponsor Name for Zolinza
Sponsor Trials
National Cancer Institute (NCI) 76
Merck Sharp & Dohme Corp. 31
M.D. Anderson Cancer Center 18
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zolinza
Sponsor Trials
Other 122
NIH 79
Industry 49
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
Colorcon
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.